OncoMatch/Clinical Trials/NCT06997029
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Is NCT06997029 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including BMS-986500 and Palbociclib for advanced solid tumor.
Treatment: BMS-986500 · Palbociclib · Fulvestrant — The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Breast Carcinoma
Ovarian Cancer
Biomarker criteria
Required: CCNE1 amplification
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Cardiac function
Participants must not have impaired cardiac function or clinically significant cardiac disease
Participants must not have impaired cardiac function or clinically significant cardiac disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Alabama at Birmingham · Birmingham, Alabama
- Providence St. Jude Medical Center · Fullerton, California
- Marin Cancer Care · Greenbrae, California
- Moores Cancer Center · La Jolla, California
- Hoag Memorial Hospital Presbyterian · Newport Beach, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify